Navigation Links
Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Date:8/10/2008

MIAMI, Aug. 11 /PRNewswire/ -- Novis Pharmaceuticals, a leading distributor of biotherapeutic products to healthcare providers, announced today that John W. Kilgour has been named Executive Vice President of Sales and Marketing. John is a healthcare professional with thirty-five years of business and management experience in both pharmaceutical and medical/surgical supply chain distribution.

Recently retired from Cardinal Health, John held positions of increasing responsibility for more than 35 years and most recently served as Vice President of Sales in Cardinal's Pharmaceutical Supply Chain Program. Primary responsibilities included sales to Integrated Delivery Networks (IDNs) and particular emphasis on resource leadership, coaching and developing Cardinal's related sales groups. Other key positions within Cardinal Health included sales management to national and regional Group Purchasing Organizations (GPOs) as well as managing pharmaceutical and medical supply sales and marketing initiatives for the acute care and managed care business segments.

Tom Burke, President and CEO of Novis Pharmaceuticals, said, "John will be a great mentor and teacher for our employees and an even better advocate for our customers. He has established longstanding, solid relationships and has a reputation of going the extra mile for clients, employees, and especially patients. His knowledge of the industry is second to none and we consider ourselves very fortunate to have him as part of the Novis team."

"I am excited to be here," added John Kilgour. "I am very impressed with Novis' core competencies and the really exceptional people who work here. This is a talented, enthusiastic and energetic group dedicated to exceeding customer expectations while meeting important patient need. Simply stated, the 'customer relationship' and 'dedication to patient need' is paramount in all that we do."

"This is a very challenging time in our industry," he continued.
'/>"/>

SOURCE Novis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
2. Novis Pharmaceuticals Hires Lisa Lopez
3. Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
4. Inovis Sponsors ASC X12 Conference, Exhibits BizManager and Secure Link
5. Renovis Announces Management Changes
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
7. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
8. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
9. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
10. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
11. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... a new report detailing the continued use of ... federal regulators that specifically discouraged these procedures. According ... that the potential cancer risks associated with power ...
(Date:9/22/2014)... Gray HealthDay Reporter MONDAY, ... woman wonders: What can I do to help ensure a ... as prescribed may play a role in reducing the risk ... The researchers found that mothers of children with autism were ... during pregnancy than those whose children seem to be developing ...
(Date:9/22/2014)... In a continued effort to support ... is launching an awareness campaign inspired by the ice ... aims to raise awareness and funds for the cause. ... in the air and trying to catch it while ... a nominee does not complete the challenge within 24 ...
(Date:9/22/2014)... Ind. Researchers have developed a chip capable ... use the new system to test the effectiveness ... new system, called a tumor-microenvironment-on-chip (T-MOC) device, will ... tumors and the barriers that prevent the targeted ... Purdue University associate professor of mechanical engineering., Researchers ...
(Date:9/22/2014)... 22, 2014 The New York Group ... Surgery at the Icahn School of Medicine at Mount ... Group for Plastic Surgery gives residents of New York ... team of world-renowned plastic surgeons performing innovative reconstructive and ... MD, who led NYGPS, was named the Director of ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... 24 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, has announced the appointment of Dr. Marcel ... Affairs. Prior to joining Sopherion, Dr. Rozencweig was ... and a member of the Sopherion Protocol Development ...
... ON, Feb. 24 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: ... research and development of drug products delivered to and ... delivery technologies, today announced that Nuvo,s INSIGHT(TM) platform, developed ... fqubed, Inc., has been selected as one of four ...
... of Nearly 106 Million PrescriptionsStrong 2009 EPS Guidance ReaffirmedFourth-Quarter ... percent to $0.54 from $0.38 in 2007 , - ... from the 2003 spin-off, increased 37.2 percent to $0.59 ... volume of 26.7 million increased 9.4 percent from 2007 ...
... a medical imaging and diagnostic Company launches new Physician Billing Services ... billing services as part of its commitment to synergistically diversify the ... ... 2009 -- Bederra Corporation (Pink Sheets: BEDA), a medical ...
... 24 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and year ended December 31, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO )For ... loss of $33.4 million, or $0.91 per share, compared ... per share, in the fourth quarter of 2007. Weighted ...
... Healthcare Workers from Hazardous Drug ExposureCOLUMBUS, Ohio, Feb. 24 ... the safe handling of hazardous drugs in the healthcare ... Safe Handling Awareness Month with Monday, April 20, 2009 ... The proclamation of National Safe Handling Awareness Month ...
Cached Medicine News:Health News:Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 2Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 4Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 5Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 6Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 7Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 8Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 9Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 10Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 11Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 12Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 13Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 14Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 15Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 16Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 17Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 18Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 19Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 20Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 21Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 22Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 23Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 24Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 25Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 26Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 27Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 28Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 29Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 30Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 2Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 3Health News:Rigel Announces Fourth Quarter and Year End 2008 Financial Results 2
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
(Date:9/22/2014)... LITTLE FALLS, N.J. , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL ... for its fourth quarter and fiscal 2014 ended July 31, ... hold a conference call to discuss the results at 11:00 ... M. Diker , Chairman; Andrew A. Krakauer , President ... and COO; Craig A. Sheldon , Senior Vice President, ...
(Date:9/22/2014)... 22, 2014  Sutro Biopharma today announced that it ... of 2014,s Fierce 15 biotechnology companies, designating it as ... the industry.  "Sutro has earned some ... well as industry partners for what promises to be ... says John Carroll , editor of FierceBiotech ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... Both Shape and Volumetric Evaluation of ... Three dimensional visualization,of the right ventricle provides important ... patients with tetralogy of,Fallot (TOF), according to a paper ... 1, 107-113)., TOF is a disease that impacts ...
... April 8, 2008 ,Anesiva, Inc. (Nasdaq: ANSV ... trial evaluating Adlea(TM), its long-acting, non-opioid analgesic,drug candidate, ... In September 2007, Anesiva initiated a multicenter, ... safety and,efficacy of a single 5 or 15 ...
Cached Medicine Technology:Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 2Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: